Status: Recruiting
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a neoadjuvant treatment for patients with clinical stage III gastric or gastroesophageal junction(GEJ) adenocarcinoma.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zekuan XuUpdated: Mar 3, 2026Locations: 1
Eligibility criteria
Not listed